SpringWorks Therapeutics has been granted a patent for an improved method of treating desmoid tumors using nirogacestat. The method involves oral administration of specific doses, with adjustments based on patient response to treatment-related side effects like hypokalemia and diarrhea. GlobalData’s report on SpringWorks Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on SpringWorks Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. SpringWorks Therapeutics's grant share as of May 2024 was 7%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of desmoid tumor with nirogacestat
A recently granted patent (Publication Number: US12011434B2) outlines a method for treating desmoid tumors in patients by orally administering 150 mg of nirogacestat or its salt twice daily. The method includes specific guidelines for managing adverse reactions such as hypokalemia, diarrhea, hypophosphatemia, and liver enzyme abnormalities. In cases of severe adverse reactions, treatment may be temporarily withheld or permanently discontinued based on the severity of the reaction. The patent also mentions considerations for patients with specific genetic mutations, prior treatment history, and tumor location.
Furthermore, the patent details the dosage adjustments and monitoring parameters for patients experiencing Grade 3 adverse events, ensuring that treatment is tailored to individual patient needs. The method emphasizes the importance of resolving adverse reactions to a manageable level before resuming treatment to maintain patient safety and efficacy. By providing a structured approach to managing treatment-related complications, the patent aims to optimize the therapeutic outcomes for patients with desmoid tumors, particularly in cases of refractory or recurrent disease. The patent also highlights the significance of monitoring key parameters like liver enzymes, electrolyte levels, and dermatologic reactions to ensure the safe and effective administration of nirogacestat for treating desmoid tumors.
To know more about GlobalData’s detailed insights on SpringWorks Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
